Certifications
Medical Oncology
Hematology
American Board of Internal Medicine
Clinical Focus
Education
MD, New York Medical College
Residency, Internal Medicine
Rhode Island HospitalFellowship, Hematology
Mount Sinai Hospital
Biography
- Dr. John Mascarenhas is a clinical investigator in malignant hematology with a focus in translational research involving the Myeloproliferative Neoplasms. Dr. Mascarenhas is primarily responsible for the clinical trials arm of the Mount Sinai School of Medicine Myeloproliferative Disorders Program headed by Dr. Ronald Hoffman. This program offers phase I/II and III studies for patients with myelofibrosis, polycythemia vera, essential thrombocythemia, chronic myelogenous leukemia, and forms of acute myeloid leukemia. In addition, Dr. Mascarenhas treats patients with myelodysplastic syndrome, hypereosinophilic syndrome, systemic mastocytosis, chronic myelomonocytic leukemia and related issues.
- A Phase I/II Open Label Study of LBH589, a Novel Histone Deacetylase Inhibitor (HDACi), in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
- A Phase I/II, Open Label Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the JAK2 inhibitor AZD1480 Administered Orally to Patients with Primary Myelofibrosis (PMF) and Post-Polycythaemia Vera/Essential Thrombocythaemia Myelofibrosis (Post-PV/ET MF)
- Phase I study of GC1008 in patients with primary myelofibrosis (PMF), post-polycythemia vera/essential thrombocythemia related myelofibrosis (post-PV/ET MF) and essential thrombocythemia (ET)
Clinical trials:
Awards
2010 - 2010
Richard E. Rosenfeld Faculty Achievement Award
Publications
Mascarenhas J, Navada S, Malone A, Rodriguez A, Najfeld V, Hoffman R. Therapeutic options for patients with myelofibrosis in blast phase. Leukemia Research 2010 June; 34(9): 1246-1249.
Industry Relationships
Physicians and scientists on the faculty of Mount Sinai School of Medicine often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Mascarenhas did not report having any of the following types of financial relationships with industry during 2011 and/or 2012: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://www.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Annenberg Building Floor Atran E Room ABE-09
1468 Madison Avenue
New York, NY 10029
Fax: 212-876-5276
1190 5th Avenue
New York, NY 10029
- Spanish